William E. Pierceall
YOU?
Author Swipe
View article: Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis
Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis Open
Neutrophils are crucial immune cells with complex and heterogeneous transcriptional programs. To understand the dynamic changes governing human granulopoiesis, we previously developed an ex vivo myeloid cell differentiation assay using hum…
View article: Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival Open
Background Multiple Myeloma (MM) patients exhibit dysregulated immune system, which is further weakened by chemotherapeutic agents. While cereblon-modulating agents, such as pomalidomide and lenalidomide, have been found to improve the imm…
View article: Supplementary Figure 6 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Supplementary Figure 6 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
PDF file - 101K, EU-5148 inhibits Mcl-1-Bim protein interaction.
View article: Supplementary Figure 5 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Supplementary Figure 5 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
PDF file - 98K, Bcl-xL depletion sensitizes lung cancer cells to therapeutic insult but does not fully rescue TWEAK-induced cell survival.
View article: Supplementary Figure 4 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Supplementary Figure 4 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
PDF file - 35K, TWEAK exposure enhances Mcl-1 and Bcl-xL mRNA expression.
View article: Supplementary Methods and Figure Legends from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Supplementary Methods and Figure Legends from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
PDF file - 113K
View article: Supplementary Figure 3 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Supplementary Figure 3 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
PDF file - 61K, Mcl-1 gene expression correlates with higher stage and worse prognosis in NSCLC.
View article: Data from BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia
Data from BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia Open
As acute myelogenous leukemia (AML) patient response to cytarabine-based standard-of-care treatment is variable, stratification into subgroups by biomarker-predicted response may lead to improved clinical outcomes. Here, we assess cell mit…
View article: Data from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Data from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
Insensitivity to standard clinical interventions, including chemotherapy, radiotherapy, and tyrosine kinase inhibitor (TKI) treatment, remains a substantial hindrance towards improving the prognosis of patients with non–small cell lung can…
View article: Data from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Data from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
Insensitivity to standard clinical interventions, including chemotherapy, radiotherapy, and tyrosine kinase inhibitor (TKI) treatment, remains a substantial hindrance towards improving the prognosis of patients with non–small cell lung can…
View article: Data from BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia
Data from BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia Open
As acute myelogenous leukemia (AML) patient response to cytarabine-based standard-of-care treatment is variable, stratification into subgroups by biomarker-predicted response may lead to improved clinical outcomes. Here, we assess cell mit…
View article: Supplementary Methods and Figure Legends from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Supplementary Methods and Figure Legends from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
PDF file - 113K
View article: Supplementary Figures 1 - 2 from BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia
Supplementary Figures 1 - 2 from BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia Open
PDF file - 79K, Supplementary Figure 1. BH3 Profiling representative patient data; Supplementary Figure 2. BH3 Profiling for BH3 Peptides in AML NR and CR Patients.
View article: Supplementary Figure 4 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Supplementary Figure 4 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
PDF file - 35K, TWEAK exposure enhances Mcl-1 and Bcl-xL mRNA expression.
View article: Supplementary Figure 1 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Supplementary Figure 1 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
PDF file - 26K, Chemical scaffold structure of EU5148.
View article: Supplementary Figure 7 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Supplementary Figure 7 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
PDF file - 53K, Pharmacologic inhibition of Mcl-1 abrogates TWEAK-mediated cell survival.
View article: Supplementary Figure 3 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Supplementary Figure 3 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
PDF file - 61K, Mcl-1 gene expression correlates with higher stage and worse prognosis in NSCLC.
View article: Supplementary Figure 2 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Supplementary Figure 2 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
PDF file - 159K, Mcl-1 and Fn14 gene expressions correlate in squamous cell lung carcinoma.
View article: Supplementary Figure 1 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Supplementary Figure 1 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
PDF file - 26K, Chemical scaffold structure of EU5148.
View article: Supplementary Figure 5 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Supplementary Figure 5 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
PDF file - 98K, Bcl-xL depletion sensitizes lung cancer cells to therapeutic insult but does not fully rescue TWEAK-induced cell survival.
View article: Supplementary Figure 7 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Supplementary Figure 7 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
PDF file - 53K, Pharmacologic inhibition of Mcl-1 abrogates TWEAK-mediated cell survival.
View article: Supplementary Figure 2 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Supplementary Figure 2 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
PDF file - 159K, Mcl-1 and Fn14 gene expressions correlate in squamous cell lung carcinoma.
View article: Supplementary Figure 6 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response
Supplementary Figure 6 from Mcl-1 Mediates TWEAK/Fn14-Induced Non–Small Cell Lung Cancer Survival and Therapeutic Response Open
PDF file - 101K, EU-5148 inhibits Mcl-1-Bim protein interaction.
View article: Supplementary Figures 1 - 2 from BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia
Supplementary Figures 1 - 2 from BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia Open
PDF file - 79K, Supplementary Figure 1. BH3 Profiling representative patient data; Supplementary Figure 2. BH3 Profiling for BH3 Peptides in AML NR and CR Patients.
View article: Supplementary Figure from Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
Supplementary Figure from Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma Open
Supplementary Figure from Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
View article: Supplementary Table from Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
Supplementary Table from Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma Open
Supplementary Table from Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
View article: Supplementary Table from Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
Supplementary Table from Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma Open
Supplementary Table from Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
View article: Supplementary Table from Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
Supplementary Table from Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma Open
Supplementary Table from Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
View article: Supplementary Data from Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
Supplementary Data from Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma Open
Supplementary Methods and Data